Preliminary Programme



Afternoon 14.30 – 19.00
Committee Meetings



Session 1 - New Targets, New Molecules
Chairs: Paola Perego, Eric Raymond
07:30Welcome Desk Opens
08:00-08:30 Welcome (Giovanni Codacci-Pisanelli, Italy)
08:30-09:00 Screening of natural molecules: the COST-Action (Bruno Botta, Italy)
09:00-09:30 GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors (Filippo Minutolo, Italy)
09:30-10:00 Mitochondrial dysfunction as a target (Padraig D’Arcy, Sweden)
10:00-10:30 Coffee Break and Poster Viewing
10:30-11:00 Protein tyrosine phosphatase SHP2 as a target for PTPN11-associated malignancies and other cancers (Lorenzo Stella, Italy)
11:00-11:30 Pharmacological challenges and possibilities to optimize the treatment with oral targeted oncolytics (Nielka Van Erp, Netherlands)
Session 2 - Biotech Session
Chairs: Jean-Pierre Bizzari, Eric Raymond
11:30-11:45Stage-defined, transgenic immunocompetent mouse model (ASV-B) to investigate new drugs for hepatocellular carcinoma (Annemilaï Tijeras-Raballand, France)
11:45-12:00AsiDNA™ A first-in-class compound targeting DNA damage response (DDR) (Françoise Bono, France)
12:00-12:15Proposal for a Pharmacodynamic model to sustain a rational /targeted development in cancer (José Jimeno, USA)
12:15-12:30Targeting MET/HGF-signaling: from preclinical evidence to clinical data (Sandrine Faivre, France)
12:30-12:45A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies (Monica Mita, USA)
12:45-13:00First-in-Human CAR-T cell therapies: Promises and Challenges (Eric Raymond, France)
13:00-14:00Lunch Break
Session 3 – Brain, Pediatric and Rare Tumors
Chairs: Monica Mita, Nadia Zaffaroni
14:00-14:30Models of rare sarcomas (Nadia. Zaffaroni, Italy)
14:30-15:00Introducing new agents into the next international trial for rhabdomyosarcomas (Janet Shipley, UK)
15:00-15:30Paediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma: models and intratumour heterogenenity (Maria Vinci, UK)
15:30-16:00Coffee Break and Poster Viewing
Session 4 – Immunotherapy
Chairs: Markus Joerger, Simona Taverna
16:00-16:30 How to select patients for immunotherapy treatment (Alejandro Navarro, Spain)
16:30-17:00 Financial toxicity of immunotherapy (Andrea Bonetti, Italy)
Session 5 – Proffered Papers (I)
Chairs: G.J. Peters, Eric Raymond
17:00-17:10 Prospective study on the role of cytidine deaminase activity in lung cancer patients treated with gemcitabine-platinum-based chemotherapy (Carmelo Tibaldi, Italy)
17:10-17:20 SPARC aberrant methylation in lung cancer (Federico Pio Fabrizio, Italy)
17:20-17:30 Oncoleaking therapy: combining chemo- and gene therapy for improved selectivity of cancer cell eradication (Wolfgang Walther, Germany)
17:30-17:40 NSCLC cells sensitive to EGFR tyrosine kinase inhibitors internalize exosomes released by NSCLC resistant cells (Pablo Reclusa, Belgium)
17:40-17:50 Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer (Joseph Pinto, Peru)
17:50-18:00 The MACC1 interactome as possible intervention point of receptor tyrosine kinase signaling in colorectal cancer metastasis (Fabian Zincke, Germany)
18:00-18:10 Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? (Joseph Pinto, Peru)
Session 6 – Epigenetics and microRNAs
Chairs: G.J. Peters, Eric Raymond
09:00Welcome Desk Opens
10:00-10:30Epigenetic treatment of drug-resistant tumours (Paola Perego, Italy)
10:30-11:00microRNAs for the therapy and diagnosis of drug resistant melanomas (Gennaro Ciliberto, Italy)
11:00-11:30Coffee Break and Poster Viewing
11:30-12:00 Targeting epigenome in cancer treatment and prevention (Lucia Altucci, Italy)
12:00-12:30Bromodomain and acetyl transferase inhibitors (Stefan Knapp, UK)
12:30-13:00Targeting epigenetic players in Rhabdomyosarcoma (Rossella Rota, Italy)
13:00-14:30Lunch Break
14:30-15:00PAMM Business Meeting
Session 7 – Breast Cancer: triple negatives, aggressive cancers
Chairs: Brian Leyland-Jones, Andrew Westwell
15:00-15:30What's New in Breast Cancer Biology (Michèle Sabbah, France)
15:30-16:00The role of Ex-Vivo Culture in Genomic Drug matching (Brian Leyland-Jones, USA)
16:00-16:30Bcl3 inhibitors (Andrew Westwell, UK)
16:30-17:00Coffee Break and Poster Viewing
Session 8 – Proffered Papers (II)
Chairs: G.J. Peters, Eric Raymond
17:00-17:10 Novel bioluminescent chick chorioallantoic membrane (CAM) models from primary pancreatic cancer (PDAC) cells unravel the modulation of key microRNAs in crizotinib/gemcitabine synergistic interaction (Niccola Funel, Italy)
17:10-17:20 Development of novel apoferritin formulations for anittumour benzothiazoles (Alastair Breen, United Kingdom)
17:20-17:30 α2β1 integrins are potential regulators of chemoresistance through modulation of biomechanical cues in pancreatic cancer (Stefano Coppola, Netherlands)
17:30-17:40 Statins markedly potentiate aminopeptidase inhibitor (pro)drug activity in acute myeloid leukemia cells (Guerrit Jansen, Netherlands)
17:40-17:50 Development of a fluorescence in situ hybridization (FISH) method for detection of intra-tumor bacteria involved in pancreatic cancer chemoresistance (Ilaria Carnevale, Netherlands)
17:50-18:00 Evaluation of Covariate Effects on the Pharmacokinetics of Dexamethasone in Childhood Acute Lymphoblastic Leukaemia Patients using Population Pharmacokinetics (Georg Hempel, Germany)
Session 9 – Pharmacology, Drug delivery tools
Chairs: Giovanni Codacci-Pisanelli, Elisa Giovannetti
09:00-09:30 Genomic strategies leading to improved outcome in colorectal cancer patients (Federico Innocenti, USA)
09:30-10:00 Gene expression profiling to predict responsiveness to adjuvant chemotherapy in colorectal cancer (Enrico Mini, Italy)
10:00-10:30Pharmacology of anticancer drugs in pregnancy/breastfeedding (Giovanni Codacci-Pisanelli, Italy)
10:30-11:00Coffee Break and Poster Viewing
11:00-11:30The Blood-Brain Barrier: Barrier for successful anticancer therapy ? (David J Begley, UK)
Special Lecture
Burger-Kelland PAMM Lecture
11:30-12:30 How molecular mechanisms can help clinical drug development (Annette Larsen, France)
Young Investigator PAMM 2018 Awards
12:30-12:45Best Presentation & Poster Awards
PAMM 2019 Announcements
12:45-13:00 Closing remarks from Chairs


New drugs-new targets
New delivery techniques

Tumour types

Brain tumours
Paediatric tumours
Breast cancer

Oriented sessions

Focus on breast cancer and on brain tumours
The aim will be to bring together clinicians and basic researchers

Biotech sessions

Short (10 minutes slots) might be allocated